Fatemeh Khojasteh Pour, Mahrokh Abouali Gale Dari, Mohammad Ramazii, Mona Keivan, Maryam Farzaneh
{"title":"Mesenchymal Stem Cells-Conditioned Medium; An Effective Cell-Free Therapeutic Option for <i>in vitro</i> Maturation of Oocytes.","authors":"Fatemeh Khojasteh Pour, Mahrokh Abouali Gale Dari, Mohammad Ramazii, Mona Keivan, Maryam Farzaneh","doi":"10.2174/1574888X18666221219163753","DOIUrl":null,"url":null,"abstract":"<p><p>Infertility is a major reproductive health issue worldwide. One of the main problems in infertile women is the failure to generate or release a mature egg. Therefore, the development of new technologies for <i>in vitro</i> generation or induction of mature oocytes can improve various ART procedures. Recently, stem cell-based therapy has opened a new window for several pathological complications. Mesenchymal stem cells (MSCs) are multipotent stem cells with the capacity to self-renew and differentiate into the mesodermal lineage. MSCs contain various bioactive molecules which are involved in the regulation of key biological processes. They can secret multiple paracrine factors, such as VEGF, IGF, HGF, EGF, and FGF to stimulate egg maturation. Although MSCs represent a promising source for cell therapy, the potential risk of tumor development reduces their clinical applications. Recent studies have suggested that the supernatant or conditioned medium of MSCs also contains similar components and regulates the oocyte behavior. The MSC-conditioned medium can eliminate the safety concerns associated with MSC transplantation and avoid rejection problems. Although MSC and MSC-CM could improve oocyte quality, ovarian function, and fertility, these improvements have not yet been demonstrated in clinical trials in humans. Hereby, we summarized recent research findings of MSCs-derived conditioned medium in in vitro development of immature oocytes.</p>","PeriodicalId":10979,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":"636-643"},"PeriodicalIF":2.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current stem cell research & therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1574888X18666221219163753","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0
Abstract
Infertility is a major reproductive health issue worldwide. One of the main problems in infertile women is the failure to generate or release a mature egg. Therefore, the development of new technologies for in vitro generation or induction of mature oocytes can improve various ART procedures. Recently, stem cell-based therapy has opened a new window for several pathological complications. Mesenchymal stem cells (MSCs) are multipotent stem cells with the capacity to self-renew and differentiate into the mesodermal lineage. MSCs contain various bioactive molecules which are involved in the regulation of key biological processes. They can secret multiple paracrine factors, such as VEGF, IGF, HGF, EGF, and FGF to stimulate egg maturation. Although MSCs represent a promising source for cell therapy, the potential risk of tumor development reduces their clinical applications. Recent studies have suggested that the supernatant or conditioned medium of MSCs also contains similar components and regulates the oocyte behavior. The MSC-conditioned medium can eliminate the safety concerns associated with MSC transplantation and avoid rejection problems. Although MSC and MSC-CM could improve oocyte quality, ovarian function, and fertility, these improvements have not yet been demonstrated in clinical trials in humans. Hereby, we summarized recent research findings of MSCs-derived conditioned medium in in vitro development of immature oocytes.
不孕症是世界范围内的一个主要生殖健康问题。不孕妇女的主要问题之一是无法产生或释放成熟卵子。因此,开发体外生成或诱导成熟卵母细胞的新技术可以改善各种 ART 程序。最近,干细胞疗法为多种病理并发症的治疗打开了一扇新窗口。间充质干细胞(MSCs)是一种多能干细胞,具有自我更新和向中胚层分化的能力。间充质干细胞含有多种生物活性分子,参与调节关键的生物过程。它们能分泌多种旁分泌因子,如血管内皮生长因子(VEGF)、血管内皮生长因子(IGF)、血管内皮生长因子(HGF)、血管内皮生长因子(EGF)和血管内皮生长因子(FGF),以刺激卵子成熟。虽然间充质干细胞是一种很有前景的细胞治疗来源,但其潜在的肿瘤发生风险降低了其临床应用。最近的研究表明,间充质干细胞的上清液或条件培养基也含有类似成分,并能调节卵母细胞的行为。间充质干细胞条件培养基可以消除与间充质干细胞移植相关的安全问题,避免排斥问题。虽然间充质干细胞和间充质干细胞调节培养基可以改善卵母细胞质量、卵巢功能和生育能力,但这些改善尚未在人体临床试验中得到证实。在此,我们总结了间充质干细胞衍生条件培养基在未成熟卵母细胞体外发育中的最新研究成果。
期刊介绍:
Current Stem Cell Research & Therapy publishes high quality frontier reviews, drug clinical trial studies and guest edited issues on all aspects of basic research on stem cells and their uses in clinical therapy. The journal is essential reading for all researchers and clinicians involved in stem cells research.